These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35212878)

  • 61. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
    Morse E; Fujiwara RJT; Mehra S
    Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty.
    Hollander MAG; Donohue JM; Stein BD; Krans EE; Jarlenski MP
    J Gen Intern Med; 2020 Aug; 35(8):2451-2458. PubMed ID: 31792860
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Opioid dispensing and overlap in veterans with non-cancer pain eligible for Medicare Part D.
    Suda KJ; Smith BM; Bailey L; Gellad WF; Huo Z; Burk M; Cunningham F; Stroupe KT
    J Am Pharm Assoc (2003); 2017; 57(3):333-340.e3. PubMed ID: 28408172
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
    Mitchell AP; Mishra Meza A; Trivedi NU; Bach PB; Gönen M
    Oncologist; 2022 Oct; 27(10):857-863. PubMed ID: 35946837
    [TBL] [Abstract][Full Text] [Related]  

  • 65. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
    Abraham AJ; Adams GB; Bradford AC; Bradford WD
    Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates.
    Hollands S
    Adm Policy Ment Health; 2020 Jan; 47(1):73-85. PubMed ID: 31515636
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
    Powell HB; Adamson AS
    J Am Acad Dermatol; 2018 Sep; 79(3):575-577. PubMed ID: 29477736
    [No Abstract]   [Full Text] [Related]  

  • 68. A Work in Progress: National Opioid Prescription Reductions Across Orthopaedic Subspecialties in a Contemporary Medicare Sample of 5,026,911 Claims.
    Acuña AJ; Jella TK; Samuel LT; Cwalina TB; Kim TS; Kamath AF
    J Am Acad Orthop Surg Glob Res Rev; 2021 May; 5(5):. PubMed ID: 34014856
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US.
    Nguyen AM; Anderson KE; Anderson G; Johnson TV
    JAMA Ophthalmol; 2022 Sep; 140(9):855-862. PubMed ID: 35900736
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prescription drug samples: making decisions with imperfect data.
    Whittle J; Good CB
    J Gen Intern Med; 2008 Jun; 23(6):890-2. PubMed ID: 18461406
    [No Abstract]   [Full Text] [Related]  

  • 71. Exploratory descriptive analysis of opioid prescribing prevalence of nurse practitioners and the specialties associated with the top prescribers.
    Pan K; Collins A
    Int J Nurs Pract; 2020 Dec; 26(6):e12850. PubMed ID: 32368834
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Opioid Prescribing Patterns and Complications in the Dermatology Medicare Population.
    Cao S; Karmouta R; Li DG; Din RS; Mostaghimi A
    JAMA Dermatol; 2018 Mar; 154(3):317-322. PubMed ID: 29417134
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of State-Imposed Restrictions on Gabapentin with Changes in Prescribing in Medicare.
    Grauer JS; Cramer JD
    J Gen Intern Med; 2022 Nov; 37(14):3630-3637. PubMed ID: 35018568
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Opioid Prescriptions in Older Medicare Beneficiaries After the 2014 Federal Rescheduling of Hydrocodone Products.
    Kuo YF; Raji MA; Liaw V; Baillargeon J; Goodwin JS
    J Am Geriatr Soc; 2018 May; 66(5):945-953. PubMed ID: 29656382
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Opioid Prescription Among Sinus Surgeons.
    Arianpour K; Nguyen B; Yuhan B; Svider PF; Eloy JA; Folbe AJ
    Am J Rhinol Allergy; 2018 Jul; 32(4):323-329. PubMed ID: 29781284
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses.
    Hadland SE; Rivera-Aguirre A; Marshall BDL; Cerdá M
    JAMA Netw Open; 2019 Jan; 2(1):e186007. PubMed ID: 30657529
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association Between Opioid Prescribing Patterns and Abuse in Ophthalmology.
    Patel S; Sternberg P
    JAMA Ophthalmol; 2017 Nov; 135(11):1216-1220. PubMed ID: 28983558
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-acting opioid prescribing patterns of ophthalmic plastic surgeons in the medicare Part D database.
    Dryden SC; Rho JE; Nix GC; Vacheron AB; Reggie SN; Meador AG; Fleming JC; Wilson MW; Fowler BT
    Orbit; 2022 Oct; 41(5):585-590. PubMed ID: 34514944
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare part D beneficiaries from 2013 to 2018: a retrospective study.
    Esechie A; Kuo YF; Goodwin JS; Westra J; Raji MA
    BMJ Open; 2021 Nov; 11(11):e053487. PubMed ID: 34794996
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Are Opioids Out? Assessing Prescription Patterns in Plastic Surgery Using Medicare Part D Beneficiary Data.
    Maisner RS; Song A; Zhou B; Srinivasan N; Thepmankorn P; Siniakowicz C; Ayyala HS
    Ann Plast Surg; 2022 May; 88(3 Suppl 3):S266-S273. PubMed ID: 35180750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.